NEW HOPE, Pa., Nov. 22, 2016 /PRNewswire/ -- BackBeat Medical Inc., a medical technology company developing novel cardiac stimulation-based therapies for hypertension and heart failure, today announced that David Hochman, President and Co-Founder, will present an overview of the company at the 28th Annual Piper Jaffray Healthcare Conference.
BackBeat Medical Inc. is a medical technology company founded in 2010 to develop novel cardiac stimulation-based therapies for hypertension and heart failure. BackBeat has developed a patented cardiac pacing-based treatment for hypertension (HTN) called programmable hypertension control (PHC) therapy. PHC is comprised of proprietary pacing algorithms that can be readily incorporated into standard pacemakers using standard leads and standard lead placement and thus has broad applicability. PHC offers a new potent device-based HTN therapeutic alternative potentially opening up a large market to treat HTN patients, particularly HTN patients who already have or require a pacemaker. Clinical results generated to date using BackBeat's own Moderato™ pacemaker incorporating PHC algorithms demonstrate that this therapy has a substantial and sustained therapeutic effect on blood pressure as determined by both in-office cuff measurements (average reduction of 24 mmHg from baseline) and 24-hour ambulatory measurements (average reduction of 14 mmHg from baseline) with clinical follow up extending up to two years.
Media Contacts:
David Schull or Todd Davenport, Ph.D.Russo Partners, LLC(212) 845-4271(212) 845-4235 [email protected] [email protected]
Advertisement
- Presentation date: Tuesday, November 29
- Presentation time: 4:30 p.m. EST
- Location: Lotte New York Palace, New York, NY
Advertisement
BackBeat Medical Inc. is a medical technology company founded in 2010 to develop novel cardiac stimulation-based therapies for hypertension and heart failure. BackBeat has developed a patented cardiac pacing-based treatment for hypertension (HTN) called programmable hypertension control (PHC) therapy. PHC is comprised of proprietary pacing algorithms that can be readily incorporated into standard pacemakers using standard leads and standard lead placement and thus has broad applicability. PHC offers a new potent device-based HTN therapeutic alternative potentially opening up a large market to treat HTN patients, particularly HTN patients who already have or require a pacemaker. Clinical results generated to date using BackBeat's own Moderato™ pacemaker incorporating PHC algorithms demonstrate that this therapy has a substantial and sustained therapeutic effect on blood pressure as determined by both in-office cuff measurements (average reduction of 24 mmHg from baseline) and 24-hour ambulatory measurements (average reduction of 14 mmHg from baseline) with clinical follow up extending up to two years.
Media Contacts:
David Schull or Todd Davenport, Ph.D.Russo Partners, LLC(212) 845-4271(212) 845-4235 [email protected] [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/backbeat-medical-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference-300367440.html
SOURCE BackBeat Medical Inc.
